CIPN and it's Impact on Quality of Life in Patients Receiving Platinum and Taxanes - Trial NCT05829967
Access comprehensive clinical trial information for NCT05829967 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Assiut University
Timeline & Enrollment
N/A
Jun 01, 2023
Aug 01, 2024
Primary Outcome
Number of patients with CIPN who receiving taxanes and platinum,Rae of recovery in patients with CIPN who receiving taxanes and platinum
Summary
Neuropathies are a major cause of moderate to severe impairments in cancer patients.
 
 Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects
 caused by antineoplastic agents, with a prevalence from 19% to over 85%.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05829967
Non-Device Trial